Get the Stockscreener App
136.25
1.58%
2.0895
Jazz Pharmaceuticals Plc stock is traded at $136.25, with a volume of 233.08K.
It is up +1.58% in the last 24 hours and down -0.39% over the past month.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
See More
Previous Close:
$134.16
Open:
$135.8
24h Volume:
233.08K
Relative Volume:
0.34
Market Cap:
$8.35B
Revenue:
$3.99B
Net Income/Loss:
$463.16M
P/E Ratio:
19.19
EPS:
7.1
Net Cash Flow:
$1.10B
1W Performance:
-0.12%
1M Performance:
-0.39%
6M Performance:
+25.27%
1Y Performance:
+15.72%
1-Day Range:
$135.15
$138.33
1-Week Range:
$133.99
$141.36
52-Week Range:
$99.06
$148.06
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Name
Jazz Pharmaceuticals Plc
Sector
Industry
Phone
353-1-634-7800
Address
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
136.30 | 8.35B | 3.99B | 463.16M | 1.10B | 7.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
499.82 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.26 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
577.62 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.88 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.54 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Upgrade | UBS | Neutral → Buy |
| Feb-26-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-13-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-12-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-05-24 | Initiated | Goldman | Buy |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Nov-27-23 | Downgrade | UBS | Buy → Neutral |
| Sep-29-23 | Initiated | Raymond James | Mkt Perform |
| Jun-12-23 | Resumed | Wells Fargo | Equal Weight |
| Dec-09-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-14-22 | Initiated | UBS | Buy |
| Apr-06-22 | Downgrade | Goldman | Buy → Neutral |
| Nov-19-21 | Resumed | Goldman | Buy |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Oct-05-21 | Initiated | Citigroup | Buy |
| Sep-23-21 | Initiated | Needham | Buy |
| May-19-21 | Resumed | JP Morgan | Overweight |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-03-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-29-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-09-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-14-20 | Downgrade | Goldman | Neutral → Sell |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-06-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-28-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jul-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-06-20 | Initiated | Jefferies | Buy |
| Mar-12-20 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Neutral |
| Aug-21-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jun-11-19 | Initiated | Barclays | Overweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Peer Perform |
| Nov-08-18 | Reiterated | B. Riley FBR | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Jul-11-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-23-18 | Reiterated | H.C. Wainwright | Neutral |
| Mar-19-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Jazz Pharmaceuticals Plc Stock (JAZZ) Latest News
Jazz Pharmaceuticals EVP sells shares worth $332,604 By Investing.com - Investing.com South Africa
Jazz Pharmaceuticals and Boston Beer Company have been highlighted as Zacks Bull and Bear of the Day - Zacks Investment Research
Bull of the Day: Jazz Pharmaceuticals (JAZZ) - Yahoo Finance
Insider Sell: Bruce Cozadd Sells 6,500 Shares of Jazz Pharmaceuticals PLC (JAZZ) - GuruFocus.com
Bull Of The Day: Jazz Pharmaceuticals (JAZZ) - Barchart
H.C. Wainwright lifts Jazz stock target to $217, maintains Buy By Investing.com - Investing.com UK
Charles Schwab Investment Management Inc. Grows Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - Defense World
HC Wainwright Issues Positive Forecast for Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price - Defense World
DraftKings To Rally Over 29%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga India
Victory Capital Management Inc. Increases Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals (NASDAQ:JAZZ) Upgraded at UBS Group - Defense World
Robert Iannone Sells 7,080 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock - Defense World
Morgan Stanley Reiterates “Overweight” Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ) - Defense World
Truist Financial Boosts Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target to $230.00 - Defense World
UBS Upgrades Jazz Pharmaceuticals (JAZZ) - Nasdaq
Jazz Pharmaceuticals Plc to Host Earnings Call - ACCESS Newswire
Needham & Company LLC Reiterates Buy Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ) - Defense World
UBS Upgrades Jazz Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $179 From $145 - Marketscreener.com
UBS raises Jazz Pharmaceuticals stock rating to Buy, target to $179 By Investing.com - Investing.com UK
Insider Selling: Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CAO Sells 4,813 Shares of Stock - MarketBeat
The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals - Nasdaq
Biotech Stocks Roundup: CMRX Up on JAZZ Bid, MRNA Up on Updates & More - Yahoo Finance
Jazz Pharmaceuticals at TD Cowen Conference: Strategic Growth in Focus By Investing.com - Investing.com UK
Truist Raises PT on Jazz Pharmaceuticals to $230 From $220 on Heels of Announced Purchase of Chimerix, Keeps Buy Rating - Marketscreener.com
Jazz Offers to Buy Chimerix for $935M to Boost Oncology Portfolio - MSN
Jazz Offers To Buy Chimerix For $935M To Boost Oncology Portfolio - Barchart
Truist lifts Jazz Pharma stock target to $230 on promising pipeline - Investing.com UK
Truist Raises Price Target on Jazz Pharmaceuticals to $230 From $220, Keeps Buy Rating - Marketscreener.com
Jazz Pharma to acquire Chimerix for ~$935M in cash - MSN
Jazz Seeks To Augment Rare Cancer Portfolio With Chimerx Buyout - Citeline News & Insights
Jazz Pharmaceuticals to acquire Chimerix for $935 million By Investing.com - Investing.com Canada
Chimerix brings a rare cancer drug to the $935M Jazz party - BioWorld Online
3 Highly Ranked Medical Stocks To Buy Amid Recent Market Volatility: JAZZ, OPCH, PCRX, - Barchart
Chimerix’s alignment with FDA on submission drives $935M takeout by Jazz - BioCentury
3 Highly Ranked Medical Stocks to Buy Amid Recent Market Volatility: JAZZ, OPCH, PCRX, - Nasdaq
A Glimpse Into The Expert Outlook On Jazz Pharmaceuticals Through 12 Analysts - Benzinga
Executive VP & Chief Legal Officer Neena Patil Sold A Bunch Of Shares In Jazz Pharmaceuticals - Simply Wall St
Jazz Buys ChimerixA Good Deal To Make With Major Approval Catalyst In Play - Seeking Alpha
3 Firms Build Jazz Pharmaceuticals' $935M Chimerix Buy - Law360
Jazz Pharmaceuticals bids for Chimerix in $935m deal - Pharmaceutical Technology
Jazz expands in oncology with $935M deal for Chimerix - BioPharma Dive
Chimerix a Prime Acquisition Candidate for Jazz Pharmaceuticals Due to Dordaviprone, Wedbush Says - Marketscreener.com
Jazz Pharmaceuticals plc entered into a definitive agreement to acquire Chimerix, Inc. for approximately $930 million. - Marketscreener.com
Jazz Pharma aims to boost cancer drug pipeline with $935 million buyoutSan Francisco Business Times - The Business Journals
Hold Rating Issued Amidst Chimerix Acquisition by Jazz Pharmaceuticals - TipRanks
Jazz Pharmaceuticals Acquires Chimerix In $935 Million Deal - Finimize
Jazz Pharmaceuticals to buy Chimerix for $935 million - MLex
Jazz Pharmaceuticals to Acquire Chimerix for $935M - Contract Pharma
Jazz Pharmaceuticals buys Chimerix for $935 million - Green Market Report
Jazz Pharmaceuticals To Acquire Chimerix For $935 Million - citybiz
Jazz Pharma To Buy Chimerix For $935 Million, Strengthening Rare Cancer Pipeline - Benzinga
Jazz Pharmaceuticals Plc Stock (JAZZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
Jazz Pharmaceuticals Plc Stock (JAZZ) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Carr Patricia | SVP, Chief Accounting Officer |
Mar 10 '25 |
Sale |
137.81 |
1,140 |
157,103 |
7,012 |
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):